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Abstract
Background: Patients presenting with acute pancreatitis may have co-existing chronic pancreatitis, the accurate diagnosis of
which would potentially guide appropriate management. Gold standard tests are often invasive, costly or time-consuming,
but the faecal elastase-1 assay has been shown to be comparatively accurate for moderate and severe exocrine deficiency.
This study aimed to evaluate fecal elastase-1 concentration [FE-1] against clinical criteria for chronicity in an acute setting.
Patients and methods: [FE-1] was performed on patients admitted with acute onset of epigastric pain and a serum lipase at
least three times the upper limit of normal. Clinical diagnosis of chronic pancreatitis was defined by the presence of specific
clinical, pathological or radiological criteria. A [FE-1] value of B/200 mg/g was similarly considered indicative of chronic
exocrine insufficiency. Thus a 2/2 table comparing [FE-1] and clinical diagnosis was constructed. Results: After exclusion
of liquid stool specimens, 105 stool specimens from 87 patients were suitable for [FE-1] determination. [FE-1] was
evaluated against the clinical diagnosis of chronic pancreatitis, initially for the whole sample, and then after exclusion of
cases of moderate and severe acute pancreatitis (Ranson score /2). The latter analysis, based on an exocrine insufficiency
threshold of 200 mg/g, yielded a sensitivity of 79.5%, specificity of 98.0%, positive predictive value of 96.9% and negative
predictive value of 86.0%. Conclusion: [FE-1] is an accurate screening tool for underlying chronic exocrine insufficiency
when taken in the course of a hospital admission for mild acute pancreatitis.
Key Words: Faecal elastase-1, diagnostic tests, chronic pancreatitis, acute pancreatitis
Introduction
The Marseille-Rome classification of 1988 [1] defines
pancreatitis as either acute or chronic, eliminating the
previous categories of acute relapsing and chronic
relapsing pancreatitis. Acute pancreatitis is an acute
inflammatory process of the pancreas with variable
involvement of other regional tissues or remote organ
systems [2]. Histological and physiological changes
are potentially reversible. By contrast, chronic
pancreatitis is a chronic inflammatory process
characterized by irreversible or progressive fibrosis of
the pancreas [3]. Clinical manifestations include
chronic epigastric pain (continuous or with intermit-
tent exacerbations) and variable degrees of exocrine
insufficiency (malabsorption with steatorrhoea,
weight loss) and endocrine insufficiency (diabetes).
While the exact prevalence of chronic pancreatitis in
various populations is difficult to determine for
logistic reasons, the annual incidence of acute
pancreatitis has been reported as anywhere between
4.8 and 24.2 per 100 000 [4]. It thus represents a
significant proportion of the admissions to digestive
surgery units.
Despite the apparent dichotomy of disease defini-
tion, it is evident that the two processes may occur
simultaneously in some patients. In any clinical
population, a proportion of incident cases of acute
pancreatitis, defined by the usual diagnostic criteria,
may harbour evolving chronic disease [5]. The latter
diagnosis is in practice based on clinical supposition,
and then often only when symptoms of malabsorption
or diabetes are overtly manifest. Early recognition
of patients with underlying chronic pancreatitis is
nevertheless useful so as to tailor a differential
management pathway compared to those with purely
acute disease.
Direct diagnostic tests of exocrine pancreatic func-
tion, such as the secretin-caerulein test [6], secretin-
cholecystokinin test [7] and the Lundh meal [8], tend
to be expensive, invasive or inconvenient. They are
thus of limited use in all but academic practice. In the
last several years, measurement of the faecal concen-
tration of pancreatic elastase-1 ([FE-1]) has emerged
as a relatively simple and non-invasive method of
detecting exocrine insufficiency [9]. Additional po-
tential advantages include specificity for pancreas
[10], stability during intestinal transit, at 488C for
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72 hours and at /208C for up to 12 months [1013],
concentration in faeces compared to pancreatic juice
[11] and non-cross-reactivity with therapeutic enzyme
supplements [14].
Measured by the ELISA method, [FE-1] has
compared favourably in terms of diagnostic efficacy
to other indirect tests of pancreatic exocrine function
including faecal chymotrypsin estimation [9,14,15],
the para-aminobenzoic acid test [13] and the pan-
creolauryl test [14,16]. However, Lankisch et al.
concluded that [FE-1] was not distinctly superior to
faecal chymotrypsin estimation, particularly in mild or
moderate forms of chronic pancreatitis [17]. Similar
conclusions were drawn when comparing [FE-1] to
the direct Lundh test [18].
This study has thus set out to determine the
diagnostic efficacy of [FE-1] in a purely clinical
setting where it is applied to opportunistic detection
of underlying chronic pancreatitis in patients present-
ing with acute pancreatitis.
Patients and methods
All patients admitted with acute pancreatitis to a
single regional hospital were consecutively recruited
as part of an ongoing prospective cohort study.
Diagnosis was based on the generally accepted criteria
of a threefold or greater increase in serum lipase and
typical epigastric pain [19]. The Cairns Base Hospi-
tal, in the far north of Queensland, Australia, serves a
population of approximately 250 000 from an area of
/500 000 square kilometres. Indigenous Australians
(Aborigines and Torres Strait Islanders) constitute
about 12% of the population [20]. A previous retro-
spective study in this population has shown the
aetiology of pancreatitis to be alcoholic in 62% of
cases and biliary in 18% [21]. For the purposes of the
present study, aetiology was defined as biliary if
gallstones were noted on standard medical imaging,
and alcoholic if there was a reported recent intake of
80 g or more of alcohol per day in the absence of other
definable risk factors such as gallstones, hypertrigly-
ceridaemia, and hypercalcaemia [22]. Severity of the
acute episode was graded according to Ranson’s
predictive scoring system [23]. An episode was
considered mild with a score of 02, moderate with
a score of 34 and severe with a score of 511.
Where possible, the first available stool specimen
was obtained from consenting patients during the
course of their admission. If no stool specimen or only
a subsequent specimen was obtained, these were
excluded from the data analysis for this study. Frankly
diarrhoeal or urine-diluted stool specimens were
also excluded, as these are known to give falsely low
[FE-1] measurements [9]. [FE-1] was measured by
the ELISA method (Schebo† Biotech, Giessen,
Germany) according to the manufacturer’s instruc-
tions. Diagnostic performance of this test was assessed
with respect to a clinical ‘gold standard’, assuming
exocrine insufficiency to be present if [FE-1] was
B/200 mg/g. This threshold is based on validated
receiver operator characteristic calculations [9,24].
For the clinical gold standard diagnosis, chronic
pancreatitis was suspected if one or more of the
following were present: a history of typical chronic
epigastric pain with no other explanation, more than
four admissions for acute pancreatitis in the previous
5 years (where alcohol was considered to be the
aetiological factor), a history of steatorrhoea, a history
of otherwise unexplained weight loss, or suggestive
features seen on medical imaging (e.g. calcification,
atrophy, ductal abnormalities, pseudocyst formation).
Diabetes mellitus was not included as a diagnostic
criterion due to the already high prevalence of type 2
disease in certain sections of the target population.
Subsequent 2/2 tables were constructed to illus-
trate true positives (TP), false positives (FP), false
negatives (FN) and true negatives (TN). Diagnostic
performance was assessed in terms of: sensitivity
/TP/(TP/FN), specificity/TN/(TN/FP), posi-
tive predictive value (PPV)/TP/(TP/FP), negative
predictive value (NPV)/TN/(TN/FN) and diag-
nostic accuracy/(TP/TN)/(TP/FP/FN/TN).
Results
Between April 2001 and May 2004, 105 suitable stool
specimens, corresponding to the same number of
admissions, were obtained from 87 patients at a
median of 4 days (range 020) after the onset of
symptoms. Twelve liquid stool specimens had been
excluded from the analysis. Eighty-nine (84.8%) of
the evaluable admissions were considered mild on the
basis of a Ranson score of 2 or less. Aetiological
attribution was alcoholic in 64 admissions (61.0%),
biliary in 24 (22.9%) and other/unknown in 27
(25.7%). [FE-1] values ranged from 0 to 920 mg/g
with a mean of 283 mg/g. In 41 (39%), [FE-1] was
measured as B/200 mg/g. Forty-one specimens (39%)
were obtained from patients in whom there was
clinical evidence of chronic pancreatitis based on the
above diagnostic criteria. The frequencies of each of
these are shown in Table I. Twenty stool specimens
(48.8%) were from patients with more than one
positive criterion, while only 15 (36.6%) showed
evidence of the later manifestations of chronic
pancreatitis (chronic pain, weight loss, steatorrhoea).
Results of the initial diagnostic performance analy-
sis are shown in Table II. When cases of moderate or
severe acute pancreatitis were excluded from the
analysis, the diagnostic performance of [FE-1] im-
proved considerably, largely due to elimination of all
but one of the original false positives (see Table III).
Discussion
This study aimed to evaluate the efficacy of [FE-1] as
an objective diagnostic tool in a practical clinical
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setting, rather than in comparison to another test of
pancreatic exocrine function. It further represents a
unique attempt to diagnose chronic pancreatitis in
incident cases of acute pancreatitis at the time of, or
just after, the acute attack. The criteria chosen for the
clinical gold standard diagnosis are all well accepted
features of chronic pancreatitis, and are no different to
what would normally be used in clinical practice to
make a provisional diagnosis. This is particularly the
case where the aetiological attribution is largely
alcoholic, as is indeed evidenced in the current sample
population and in previous epidemiological work in
the region [21].
As shown in Table II, the application of [FE-1] to
all incident cases of acute pancreatitis yielded un-
spectacular results for the usual indices of diagnostic
performance. These markedly improved after exclu-
sion of cases with moderate or severe acute disease as
predicted by Ranson’s score. Such cases were respon-
sible principally for false positive results, as seen in
Table III. Exocrine function may indeed be impaired
by transient acinar cell dysfunction or frank parench-
ymal necrosis. Using [FE-1], Boreham and Ammori
[25] have shown that pancreatic exocrine insufficiency
occurs commonly in patients recovering from severe
acute pancreatitis, and its severity correlates with the
extent of necrosis documented on contrast-enhanced
CT scan. Some cases of moderate or severe acute
pancreatitis may nevertheless yield a normal [FE-1]
given the relative stability of this enzyme in the
gastrointestinal tract [12]. A stool specimen obtained
early in the course of an admission may represent that
which was in the colon just prior to the onset of the
acute attack. However, the ileus often present in
severe cases may lead to eventual degradation of the
enzyme, thus also ‘falsely’ lowering the [FE-1] mea-
surement. Indeed in this study, median time of first
stool specimen from onset of symptoms was 3 days for
mild cases (Ranson score B/3) compared with 5.5
days for moderate or severe cases (Ranson score /2).
A number of considerations would recommend the
use of [FE-1] as a cost-effective screening tool for
chronic exocrine insufficiency in patients presenting
with acute pancreatitis. Firstly, the assay itself is
relatively inexpensive and easy to perform. Stool
specimens can also be stored in a freezer at /208C
until a sufficient number has been accrued for a run.
Secondly, with a specificity of 98% and positive
predictive value of 96.9%, a positive result can
generally be relied upon. Furthermore, PPV is opti-
mized when the target screening population has a
relatively high prevalence of the disease in question
[26]. This would seem to be the case in patients
presenting with attacks of acute pancreatitis, particu-
larly where the predominant aetiological factor is
alcohol, as in this sample population. Thirdly,
although [FE-1] is demonstrably less reliable when
dealing with moderate or severe cases of pancreatitis,
the vast majority of incident cases are typically mild
[2], as is also seen in the current series. Lastly,
patients with chronic pancreatitis, particularly when
alcohol-related, often pose problems for compliance
and follow-up. A non-invasive test such as [FE-1]
measured once during the course of a hospital
admission is thus more feasible than most of the other
diagnostic tests currently available.
It should be noted that 39% of the sample popula-
tion showed evidence of chronic exocrine insuffi-
ciency based of a [FE-1] B/200 mg/g. Extrapolation
of this prevalence to the overall target population must
take into account the fact that an estimated 30% of
incident cases were initially excluded due to unavail-
ability of a stool specimen or delayed specimen
collection (i.e. not the first one after symptom onset).
It is nevertheless difficult to conceive a specific
selection bias under these circumstances in favour of
any particular clinicopathological subgroup.
What to do with a positive [FE-1] result remains
open to the outcomes of ongoing basic and clinical
research. It is conceivable that chronic pancreatitis
diagnosed prior to the development of the end-stage
Table I. Diagnostic criteria for chronic pancreatitis.
Criterion Number of
patients
Percentage of diagnosis
positive group
At least one criterion 41 100%
Recurrent admissions 26 63.4%
Positive imaging 20 48.8%
Chronic pain 9 22.0%
Weight loss 6 14.6%
Steatorrhoea 5 12.2%
Table II. [FE-1] compared to clinical diagnosis: all cases.
[FE-1] Clinical diagnosis
positive
Clinical diagnosis
negative
Totals
[FE-1] B/200 mg/g 32 9 41
[FE-1] /200 mg/g 9 55 64
Totals 41 64 105
Sensitivity/78%, specificity/76.6%, positive predictive value
(PPV)/78%, negative predictive value (NPV)/85.9%,
diagnostic accuracy/82.9%.
Table III. [FE-1] compared to clinical diagnosis: mild acute pan-
creatitis (Ranson score B/3).
[FE-1] Clinical diagnosis
positive
Clinical diagnosis
negative
Totals
[FE-1] B/200 mg/g 31 1 32
[FE-1] /200 mg/g 8 49 57
Totals 39 50 89
Sensitivity/79.5%, specificity/98%, positive predictive value
(PPV)/96.9%, negative predictive value (NPV)/86%,
diagnostic accuracy/89.9%.
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manifestations of intractable pain, malabsorption and
diabetes may be amenable to innovative secondary
prevention strategies. A simple objective diagnostic
test is in any case useful for defining patients suitable
for inclusion in clinical trials. Positive screening
results may also have specific epidemiological impli-
cations for the local target populations. Twelve
(31.6%) of the 38 patients in this study with [FE-1]
below 200 mg/g were indigenous Australians. This
group of patients is thus over-represented for chronic
pancreatitis when compared with the target popula-
tion as a whole. Such a result warrants culturally
orientated management strategies as well as further
studies to elucidate the precise causative factors.
In conclusion, [FE-1] is a feasible and accurate
screening test for chronic exocrine insufficiency in
patients presenting with predicted mild acute pan-
creatitis. While all acute patients are amenable to
screening, it is recommended that those with moder-
ate or severe acute disease, particularly if the initial
[FE-1] result is subnormal, should be re-screened
after 23 months to assess for residual or permanent
exocrine insufficiency. Similarly those with normal
[FE-1] but clinical features suggestive of underlying
chronic disease should undergo follow-up testing to
detect deterioration in exocrine function before more
severe clinical features manifest.
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